|
 |
 |
 |
 |
 |
 |
Buckman Laboratories and OmniLytics Agree to commercialize bacteriophage-based products for E. coli, Salmonella and Listeria Buckman Laboratories, Inc. and OmniLytics, Inc. enter into an agreement to commercialize bacteriophage-based products for E. coli, Salmonella and Listeria. Salt Lake City — (September 15, 2006) Buckman Laboratories, Inc. of Memphis, TN and OmniLytics, Inc. of Salt Lake City, UT have entered into an agreement to pursue the commercialization of bacteriophage-based products for E. coli, Salmonella and Listeria. Both firms are moving forward on a project that entails the external application of the bacteriophages to cattle, pigs, sheep and poultry livestock, both prior and post slaughter. This unique technology will reduce the threat of human enteric infections encountered through contamination associated with these pathogens. The bacteriophage products would be utilized to treat the animals, living quarters, holding areas, transportation vehicles and containers. It is also envisioned that they will be utilized to reduce the level of contamination on cattle hides prior to further processing. The utilization of bacteriophages or bacterial viruses is by no means new. They are ubiquitous in nature and all around us, being readily found in the food we eat and with in our bodies. Unlike the mechanism of action associated with organic antibacterials or broad spectrum antibiotics, the specificity of phages provides a means to address a particular strain and species of bacteria, while maintaining the viability of other natural microflora. Dean Didato, Vice President with Buckman Laboratories stated that “this unique technology provides an innovative, yet very specific means to address timely issues surrounding the reduction of pathogenic populations that pose a threat to human health and welfare. The addition of this technology nicely complements recent advances that Buckman has made with respect to the use of non-traditional means to achieve similar results previously attained only by using synthetic chemistries.” Didato mentioned that the addition of bacteriophages to the company’s product offering of Neoteric, Optimize and Aurora lines is a logical extension. Justin Reber, President & CEO of OmniLytics, offered “we are excited about this collaborative effort with Buckman Laboratories. Buckman has the experience as well as extensive resources to be able to bring bacteriophage-based products into their respective market segments. With OmniLytics’ expertise in manufacturing highly effective bacteriophage-based products for use in the food & water safety and industrial markets, and Buckman’s broad worldwide reach in these markets, we’re confident that together we can provide customers with natural, effective solutions.” About Buckman Laboritories, Inc. Buckman Laboratories, headquartered in Memphis, Tennessee, USA, is a leading manufacturer of specialty chemicals for aqueous industrial systems. The company was founded in 1945 on its unique ability to create and manufacture innovative solutions to control the growth of microorganisms. Today the company provides complete specialty chemical solutions for the pulp and paper, water treatment, and leather markets. The company has annual sales of over $462 million, produces 700 different products, and employs over 1,450 people working in more than 90 countries. For additional information about Buckman, visit www.buckman.com . OmniLytics is a biotech
company focused on developing safe, natural,
effective solutions for infectious disease and
pest control. OmniLytics is located in SLC, Utah.
OmniLytics is pioneering research and development
of bacteriophage solutions for control of microorganisms
in agricultural, food & water, industrial,
pharmaceutical, and defense markets. OmniLytics’ proprietary
formulas and processes optimize the use of natural
bacteriophage for commercial applications. For
more information about OmniLytics, visit www.omnilytics.com. Tony Swensen Business or Investments Alan Walbeck
|
Bacteriophage: The Good Virus™
 |
 |
 |
 |
 |
|
OmniLytics, Inc. is a bacteriophage company
that is focused on developing safe, natural solutions for infectious disease
control. With emphasis on bacteriophage technology,
OmniLytics is pioneering research and development of bacteriophage solutions
for pathogen control in the agricultural, food & water, industrial, pharmaceutical,
and defense markets.
Copyright © 2006 OmniLytics, Inc. All
rights reserved.